Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide for Weight Loss in Non-Diabetic Obese Subjects
NCT00856609Phase 3Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Mar 2009
- Primary completion
- Sep 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obesity comparing Exenatide with Placebo (2 arms). Primary endpoints: Energy Intake and Twenty-four-hour Energy Expenditure at Day 11. Started Mar 2009; status: completed.
02
Drugs
exenatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT00856609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00856609.